4D Molecular Therapeutics (FDMT) Competitors $5.78 +0.05 (+0.87%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$5.78 0.00 (-0.09%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. HROW, PRAX, AVDL, PAHC, PHVS, ARDX, GPCR, AMPH, VERV, and SYREShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Harrow (HROW), Praxis Precision Medicines (PRAX), Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Pharvaris (PHVS), Ardelyx (ARDX), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Verve Therapeutics (VERV), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Its Competitors Harrow Praxis Precision Medicines Avadel Pharmaceuticals Phibro Animal Health Pharvaris Ardelyx Structure Therapeutics Amphastar Pharmaceuticals Verve Therapeutics Spyre Therapeutics Harrow (NASDAQ:HROW) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations. Do institutionals and insiders have more ownership in HROW or FDMT? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 15.2% of Harrow shares are owned by company insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is HROW or FDMT more profitable? Harrow has a net margin of -10.19% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. Harrow's return on equity of -25.01% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Harrow-10.19% -25.01% -4.27% 4D Molecular Therapeutics -767,126.06%-33.26%-30.68% Which has higher valuation & earnings, HROW or FDMT? Harrow has higher revenue and earnings than 4D Molecular Therapeutics. Harrow is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M6.10-$17.48M-$0.56-59.304D Molecular Therapeutics$40K6,694.69-$160.87M-$3.18-1.82 Does the media refer more to HROW or FDMT? In the previous week, Harrow and Harrow both had 8 articles in the media. 4D Molecular Therapeutics' average media sentiment score of 0.23 beat Harrow's score of 0.17 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral 4D Molecular Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer HROW or FDMT? Harrow presently has a consensus price target of $63.83, suggesting a potential upside of 92.21%. 4D Molecular Therapeutics has a consensus price target of $29.56, suggesting a potential upside of 411.34%. Given 4D Molecular Therapeutics' higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.004D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk & volatility, HROW or FDMT? Harrow has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.83, indicating that its share price is 183% more volatile than the S&P 500. SummaryHarrow beats 4D Molecular Therapeutics on 8 of the 14 factors compared between the two stocks. Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$265.44M$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.18%P/E Ratio-1.8219.6629.8725.14Price / Sales6,694.69634.80422.9397.17Price / CashN/A165.0335.9458.58Price / Book0.524.198.105.59Net Income-$160.87M$31.61M$3.26B$265.48M7 Day Performance-9.97%0.95%0.64%1.22%1 Month Performance36.97%2.90%2.42%0.39%1 Year Performance-60.76%4.11%27.60%23.47% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.5029 of 5 stars$5.78+0.9%$29.56+411.3%-60.7%$265.44M$40K-1.82120Upcoming EarningsGap DownHROWHarrow2.4878 of 5 stars$33.42+7.0%$63.83+91.0%+51.1%$1.15B$199.61M-59.68180Upcoming EarningsPRAXPraxis Precision Medicines1.6617 of 5 stars$51.09-5.5%$94.11+84.2%-9.1%$1.10B$8.55M-4.77110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeAVDLAvadel Pharmaceuticals2.8255 of 5 stars$11.26+1.6%$18.33+62.8%-20.9%$1.07B$169.12M-41.7070News CoverageEarnings ReportGap UpPAHCPhibro Animal Health4.0912 of 5 stars$27.14+3.9%$24.40-10.1%+60.8%$1.06B$1.02B34.801,940Positive NewsPHVSPharvaris1.7062 of 5 stars$21.24+6.2%$36.20+70.4%+16.2%$1.05BN/A-7.0630Positive NewsUpcoming EarningsARDXArdelyx4.3377 of 5 stars$4.39+1.4%$10.88+147.7%-7.4%$1.04B$333.61M-19.9590Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGPCRStructure Therapeutics1.897 of 5 stars$16.78-4.6%$76.17+353.9%-52.4%$1.01BN/A-19.29136News CoverageEarnings ReportAnalyst ForecastAMPHAmphastar Pharmaceuticals4.3083 of 5 stars$21.40+0.9%$32.33+51.1%-44.4%$999.82M$731.97M7.752,028News CoverageVERVVerve Therapeutics3.3975 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110Upcoming EarningsSYRESpyre Therapeutics2.458 of 5 stars$16.16-0.6%$53.40+230.4%-37.9%$980.08M$890K-4.2973Earnings ReportAnalyst Forecast Related Companies and Tools Related Companies HROW Alternatives PRAX Alternatives AVDL Alternatives PAHC Alternatives PHVS Alternatives ARDX Alternatives GPCR Alternatives AMPH Alternatives VERV Alternatives SYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
